Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
Active, not recruiting · Phase 1 · NCT04454658
Conditions: Myelofibrosis (MF)
At a glance
- Research payments reported, 2025
- $132,315
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 21
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-744 (drug), Navitoclax (drug), Ruxolitinib (drug)
- Dates
- Started 2020-11-11; completion 2027-01
- Results posted
- Not yet
Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to see how safe and tolerable ABBV-744 is, when given alone, and in combination with ruxolitinib or navitoclax, for adult participants with MF. ABBV-744 is an investigational drug being developed for the treatment of MF. The study has 4 segments - A, B, C, and D. In Segment A, the safe dosing regimen of ABBV-744 is identified and then, given alone as monotherapy. In Segment B, C, and D, combinatio…
From ClinicalTrials.gov, last updated 2025-07-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $132,315 in research payments for this study in 2025 (19 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rasmus T. Hoeg, M.D. Hematology & Oncology · Sacramento, CA
- Steven D. Green, M.D. Internal Medicine · Buffalo, NY
- John Mascarenhas, MD Hematology & Oncology · New York, NY
- Ellen K. Ritchie, MD Medical Oncology · New York, NY
- Nashat Gabrail, M.D. Specialist · Canton, OH
- Elie A. Traer, MD, PHD Hematology & Oncology · Portland, OR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Icahn School of Medicine at Mount Sinai $50,589
- Ohsu Hospital and Clinics, OR $41,853
- Gabrail Cancer Center Research LLC $21,560
- Health Research Inc Roswell PArk Division $7,350
- Weill Medical College of Cornell University $6,333
- University of California Davis Medical Center, CA $4,630
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.